Bioventus Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Für Bioventus wird ein Gewinn- und Umsatzwachstum von 17% bzw. 6.5% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 16.2% pro Jahr steigen soll.
Wichtige Informationen
17.0%
Wachstumsrate der Gewinne
16.21%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 16.1% |
| Wachstumsrate der Einnahmen | 6.5% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 15 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • May 19
BVS: Index Inclusion And 2026 Guidance Will Support A Higher Price
Analysts have raised their Bioventus price target from $15.00 to $16.00, citing updated assumptions related to revenue growth, profit margins, discount rates, and future P/E levels. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2026, with expected net sales of US$600 million to US$610 million and implied growth of about 6% to 7% (company guidance).Analyseartikel • May 14
Statutory Profit Doesn't Reflect How Good Bioventus' (NASDAQ:BVS) Earnings Are
Investors were underwhelmed by the solid earnings posted by Bioventus Inc. ( NASDAQ:BVS ) recently. Our analysis says...
Narrativ-Update • May 01
BVS: Index Inclusion And 2026 Sales Outlook Will Support Further Upside
Analysts have maintained their Bioventus fair value estimate at $14.80 while making only small adjustments to key inputs such as the discount rate and expected future P/E, indicating fine-tuning of their valuation framework rather than a major change in outlook. What's in the News Bioventus Inc.Narrativ-Update • Apr 17
BVS: Index Addition And 2026 Sales Guidance Will Support Further Upside
Analysts have modestly fine tuned their $14.80 price target for Bioventus, keeping it steady overall as minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions leave the valuation view essentially unchanged. What's in the News Bioventus Inc.Narrativ-Update • Apr 03
BVS: Index Inclusion And 2026 Sales Outlook Will Support Further Upside
Analysts have revised their price target for Bioventus slightly lower from $15.00 to $14.80, reflecting updated fair value and discount rate assumptions while maintaining similar views on revenue growth, profit margin and future P/E expectations. What's in the News Bioventus Inc.Narrativ-Update • Mar 19
BVS: 2026 Net Sales Guidance And Margin Outlook Will Support Further Upside
Analysts have adjusted their price target on Bioventus to $15.00 from $14.50, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E that collectively support a slightly higher valuation. What's in the News Bioventus issued earnings guidance for 2026, setting expected net sales in a range of $600 million to $610 million.Narrativ-Update • Mar 05
BVS: Refined Assumptions And 2026 Outlook Will Support Further Upside Potential
Analysts have adjusted their price target on Bioventus slightly lower from $15.00 to $14.50, reflecting updated views on revenue growth, profit margins and future P/E assumptions. What's in the News Bioventus issued earnings guidance for 2026, with expected net sales of $600 million to $610 million.
Narrativ-Update • Feb 19
BVS: Higher Revenue Outlook And Richer Future P/E Will Drive Upside
Analysts have revised their Bioventus price target to $13.00 from $7.00, reflecting updated views on fair value, discount rate assumptions, revenue growth expectations, profit margin outlook and future P/E multiples. Valuation Changes Fair Value: revised to $13.00 from $7.00, indicating a higher assessed equity value per share.Narrativ-Update • Feb 05
BVS: Fine Tuned Assumptions Will Support Further Upside Potential
Analysts have nudged their price target on Bioventus to US$15.00, a modest change that reflects fine tuning to inputs such as the discount rate, long term revenue growth, profit margin assumptions, and expected future P/E rather than a shift in their overall view of the company. Valuation Changes Fair Value: Maintained at US$15.00 per share, with no change in the overall valuation output.Narrativ-Update • Jan 22
BVS: Reaffirmed 2025 Guidance And Stable Assumptions Will Support Further Upside
Analysts have kept their fair value estimate for Bioventus unchanged at US$15.00, with only slight tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. This signals a broadly steady view of the stock's risk and return profile.Narrativ-Update • Jan 07
BVS: Reaffirmed 2025 Guidance Will Support Ongoing Upside Potential
Analysts have kept their fair value estimate for Bioventus steady at US$15.00, citing only very small tweaks to inputs such as the discount rate, long term revenue growth, profit margin and future P/E assumptions that do not materially change their overall view. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2025, signaling no change to its previously communicated outlook.Narrativ-Update • Dec 20
BVS: Reaffirmed 2025 Earnings Guidance Will Support Continued Upside Potential
Analysts have nudged their price target on Bioventus slightly higher to reflect modestly stronger revenue growth expectations and a marginally lower discount rate, while keeping fair value unchanged at approximately $15.00 per share. What's in the News Bioventus reaffirmed its full year 2025 earnings guidance, signaling management confidence in the current strategic and operating plan (company guidance).Narrativ-Update • Dec 06
BVS: Earnings Guidance Will Support Continued Upside Potential In Shares
Analysts have modestly raised their price target on Bioventus to approximately $15.00 per share from about $15.00 per share, reflecting slightly lower perceived risk, stable long term growth expectations, and marginally improved profitability and valuation assumptions. What's in the News Bioventus reaffirmed its 2025 earnings guidance, projecting net sales between $560 million and $570 million.Seeking Alpha • Dec 02
Bioventus: A New Start
Summary Bioventus is regaining stability after a volatile period, with improving margins and organic sales growth driving renewed optimism. The company trades at compelling valuation multiples—below 2x sales, ~7x adjusted EBITDA, and ~11x adjusted earnings—supported by accelerating organic revenue growth. Recent refinancing is set to reduce annual interest costs by over $2 million, and net debt has declined to $280 million, lowering leverage to around 2.5x. With continued sales and margin growth, disciplined capital allocation could enable Bioventus shares to revisit the teens by 2026. Read the full article on Seeking AlphaAnalyseartikel • Nov 26
Bioventus (NASDAQ:BVS) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Narrativ-Update • Nov 22
BVS: Earnings Guidance Is Expected To Drive Share Price Higher
Analysts have updated their price target for Bioventus, raising it modestly from $14.67 to $15.00 per share. This change reflects improved revenue growth expectations, despite a slightly higher discount rate and lower projected profit margin.Narrativ-Update • Nov 03
BVS: Net Sales Guidance Will Sustain Bullish Outlook Into 2025
Analysts have slightly raised their price target for Bioventus to $14.67 per share, citing minor updates to the company's discount rate and future price-to-earnings assumptions. What's in the News Bioventus Inc.Narrativ-Update • Oct 20
Minimally Invasive Nonopioid Pain Management Will Expand With PNS
Analysts have modestly raised their price target for Bioventus, increasing it by $0.00 to $14.67. They cited slight adjustments to their discount rate and future price-to-earnings assumptions.Narrativ-Update • Oct 05
Minimally Invasive Nonopioid Pain Management Will Expand With PNS
Analysts have raised their price target for Bioventus from $12.75 to approximately $14.67 per share, citing improvements in projected revenue growth and a more favorable future price-to-earnings outlook. What's in the News Bioventus issued new earnings guidance for 2025 and estimates net sales between $560 million and $570 million.Analyseartikel • Aug 14
We Think Bioventus' (NASDAQ:BVS) Robust Earnings Are Conservative
NasdaqGS:BVS 1 Year Share Price vs Fair Value Explore Bioventus's Fair Values from the Community and select yours...Analyseartikel • Aug 09
Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next
It's been a pretty great week for Bioventus Inc. ( NASDAQ:BVS ) shareholders, with its shares surging 12% to US$6.92 in...Neues Narrativ • May 30
Cost Effective Therapies And Regenerative Medicine Will Transform Global Markets
Accelerated adoption of minimally invasive therapies and portfolio expansion in regenerative medicine are driving higher margins and capturing increased demand from demographic trends.Analyseartikel • May 07
Is Bioventus (NASDAQ:BVS) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Mar 08
Investors Aren't Buying Bioventus Inc.'s (NASDAQ:BVS) Revenues
Bioventus Inc.'s ( NASDAQ:BVS ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong buy right now...Seeking Alpha • Jan 05
Bioventus: Amply Rewarded For Recent Progress
Summary The stock of medical device concern Bioventus has roughly doubled over the past year, but has lost momentum recently. Management has done a commendable job in recent years in reducing debt and leverage ratios, and profits have rebounded significantly. What's ahead for Bioventus in 2025? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Aug 12
Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024
Summary Bioventus Inc. posted strong Q2 results, with revenue up 10.3% and a raised full-year sales forecast. The company focuses on orthobiologics and active healing products, with key products like DUROLANE and EXOGEN. Despite positive performance, high debt and tough competition could impact future profits and valuation. Read the full article on Seeking AlphaSeeking Alpha • Jan 24
Bioventus: Bullish On Path To Profitability
Summary Shares of BVS are up more than 100% over the past year amid an ongoing financial turnaround. The company is benefiting from strong demand for its portfolio of minimally invasive medical treatment including therapeutic injections for osteoarthritis. Shares are attractively priced ahead of the Q4 earnings report where we expect management to deliver positive 2024 guidance. Read the full article on Seeking AlphaGewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 687 | 47 | 108 | 105 | 3 |
| 12/31/2027 | 646 | 39 | 97 | 95 | 5 |
| 12/31/2026 | 606 | 30 | 85 | 85 | 5 |
| 3/28/2026 | 576 | 28 | 101 | 103 | N/A |
| 12/31/2025 | 568 | 23 | 72 | 75 | N/A |
| 9/27/2025 | 564 | 10 | 53 | 56 | N/A |
| 6/28/2025 | 564 | 2 | 34 | 36 | N/A |
| 3/29/2025 | 568 | -34 | 24 | 25 | N/A |
| 12/31/2024 | 573 | -36 | 37 | 39 | N/A |
| 9/28/2024 | 555 | -42 | 28 | 30 | N/A |
| 6/29/2024 | 537 | -44 | 8 | 11 | N/A |
| 3/30/2024 | 523 | -22 | 2 | 7 | N/A |
| 12/31/2023 | 512 | -97 | 8 | 15 | N/A |
| 9/30/2023 | 503 | -104 | 0 | 10 | N/A |
| 7/1/2023 | 511 | -169 | 8 | 18 | N/A |
| 4/1/2023 | 514 | -173 | -1 | 10 | N/A |
| 12/31/2022 | 512 | -104 | -25 | -14 | N/A |
| 10/1/2022 | 517 | -91 | -15 | -6 | N/A |
| 7/2/2022 | 497 | -19 | -4 | 6 | N/A |
| 4/2/2022 | 466 | -16 | 11 | 20 | N/A |
| 12/31/2021 | 431 | -5 | 9 | 23 | N/A |
| 10/2/2021 | 399 | -3 | 29 | 35 | N/A |
| 7/3/2021 | 376 | 6 | 40 | 46 | N/A |
| 4/3/2021 | 324 | 4 | 31 | 36 | N/A |
| 12/31/2020 | 321 | 16 | 55 | 72 | N/A |
| 9/26/2020 | 320 | 16 | 71 | 67 | N/A |
| 6/27/2020 | 316 | 12 | 62 | 58 | N/A |
| 3/28/2020 | 339 | 15 | 55 | 54 | N/A |
| 12/31/2019 | 340 | 9 | N/A | 41 | N/A |
| 12/31/2018 | 319 | -1 | N/A | 45 | N/A |
| 4/2/2016 | 266 | -23 | N/A | 25 | N/A |
| 12/31/2015 | 254 | -38 | N/A | 19 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: BVSDas prognostizierte Gewinnwachstum (17% pro Jahr) liegt über der Sparquote (3.5%).
Ertrag vs. Markt: BVSDie Erträge des Unternehmens (17% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (16.7% pro Jahr).
Hohe Wachstumserträge: BVSDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: BVSDie Einnahmen des Unternehmens (6.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.7% pro Jahr).
Hohe Wachstumseinnahmen: BVSDie Einnahmen des Unternehmens (6.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von BVS in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/21 15:24 |
| Aktienkurs zum Tagesende | 2026/05/21 00:00 |
| Gewinne | 2026/03/28 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Bioventus Inc. wird von 11 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Kyle Rose | Canaccord Genuity |
| Caitlin Cronin | Canaccord Genuity |